ArticleVaccine2025

Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.

Shoroq M Altawalbeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.